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Highlights 
 Metformin solid lipid nanoparticles were prepared by the ultra-sonication method 
 Solid state analysis ruled out any interaction between metformin and excipients 
 Ratio of Tween:Span had a significant influence on performance of Met-SLN 
 Gels containing Met-SLN showed better performance on the skin delivery of metformin  
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The aim of the present study was to enhance the skin delivery of metformin by making solid 
lipid nanoparticles containing metformin using the ultra-sonication method. To achieve the 
optimum skin delivery for metformin, the effects of the ratio of two surfactants (Tween:Span) on 
nanoparticles properties and their performance were investigated. Photon correlation 
spectroscopy, scanning electron microscopy (SEM), Powder X-ray Diffractometer (PXRD), 
Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) 
were used to characterize the solid state of metformin in solid lipid nanoparticles. Generally, the 
particle size of nanoparticles decreased by the addition of co-emulsifier (Span®60). Results 
showed that all formulations made by binary mixtures of surfactants had low particle size, low 
Polydispersity index and high zeta potential. It was interesting to note that the smallest 
nanoparticles (203.8±15.356) was obtained when the HLB of the binary surfactants (HLB of 
11.67) was closer to the HLB of beeswax (HLB of 12) used in the preparation of SLN. It was 
also found that by decreasing the HLB of the system from 14.9 to 10.06 the zeta potential of 
SLNs increased from -0.651±0.315 to -6.18± 0.438 mV. But, a further reduction in the HLB 
from 10.06 to 8.45 caused a reduction in the zeta potential from -6.18 to -3.596±0.255. Results 
showed that the highest entrapment efficiency of 45.98±9.20% was obtained for formulation 
with larger particle size and with the highest HLB value (HLB 14.9). DSC study showed that 
metformin in SLN is in an amorphous form.  FT-IR spectra of Met-SLN showed that the 
prominent functional groups existed in the formulations which could be an indication of good 
entrapment of metformin in a lipid matrix. FT-IR results also ruled out any chemical interaction 
between the drug and the excipients. The amounts of metformin detected in the skin layers and 
the receptor chamber at all sampling times were higher for nanogel compared to metformin gel. 
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This is an indication of a better performance of Metformin nanogel ex-vivo and could be 
developed further for clinical studies.  
Keywords: Metformin, Solid lipid nanoparticles, Ultra-sonication, DSC, FT-IR, Skin permeation 
 
1. Introduction  
In recent years the anti-inflammatory effect of metformin (Met), which is widely used as an anti-
diabetic drug, has been reported in many animal models. Met inhibits the production of reactive 
oxygen species (ROS) from nicotinamide adenine dinucleotide hydride (NADH) in 
lipopolysaccharide-activated macrophage [1-3]. Inflammation and the accumulation of ROS  
perform a vital role in the intrinsic and photoaging of human skin [4]. One of the major causes of 
skin ageing is chronic exposure to ultraviolet (UV) radiation. UVB (ultraviolet B-rays) is the 
light from the sun that has a fairly short wavelength and penetrates the skin and activates three 
major skin ageing cascades by inducing ROS production which is responsible for UVB-induced 
skin ageing [5]. In order to get a benefit from the anti-inflammatory effect of Met on the skin, the 
best option is to enhance its dermal effects, therefore, its side effects will be less through the 
topical administration route [6]. Met hydrochloride belongs to class I drugs (based on BCS 
classification) and its permeability is the rate-limiting factor that could be modified by altering 
the physiochemical properties of the drug which is a very complex task. Nanotechnology is 
another approach which can improve percutaneous drug absorption effectively without any 
chemical change in the molecular structure of drugs [7]. Among all colloidal carriers, Solid Lipid 
Nanoparticles (SLNs), due to their advantages such as improved physical stability, good 
tolerability, and ease of scale-up and manufacturing, have emerged as an alternative colloidal 
carrier [6]. Recently, SLNs have been widely used for skin delivery due to their safe interaction 
with skin layers, and improved skin permeation [6]. However, encapsulation of hydrophilic 
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drugs into the hydrophobic lipid of SLNs is a major problem because during the production 
process the drug tends to partition towards the aqueous phase. To best of our knowledge, there 
are very limited examples of hydrophilic drugs being encapsulated into SLNs [8-11], these 
include the loading isoniazid [8], ciprofloxacilline [9, 10,] and gentamicin sulfate [11] on SLN. 
In these research work, different techniques such as microemulsion [9], ultrasonication and high-
speed homogenization [10-11] were employed to manufacture SLN.   None of the above studies 
investigated the effect of HLB value of binary surfactants on the manufacturing of solid lipid 
nanoparticles containing an active pharmaceutical ingredient. Met was selected as a hydrophilic 
and anti-ageing drug to incorporate in SLNs by the ultra-sonication method, and the effect of 
HLB of surfactant mixtures on the properties of SLN was explored .The optimized Met-SLN was 
formulated as a topical gel and applied on the skin for further investigation. Based on the 
literature survey, the investigation on the effect of a mixture of surfactants on properties of 
hydrophilic drugs incorporated in solid lipid nanoparticles is lacking.  
2. Materials and Methods 
2.1 Materials 
Met was obtained from Tehran Chemie pharmaceutical Co. (Tehran, Iran). Tween 60 and 
cholesterol were obtained from Merck (Merck Co., Germany). Span 60 was obtained from 
Daejung (Daejung Chemicals & Metals Co., Ltd. Korea). Beeswax was obtained from John’s 
Laboratory (John’s laboratory chemicals, India). Distilled water was purified using a Human 
power 2 system (human Co., Korea). 
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2.2 Preparation of Met-SLN  
Met nanoparticles were prepared by the probe ultra-sonication method [8]. The mixture of 
beeswax, cholesterol, span 60 and Met were melted at below 70 ºC by a heater stirrer. The 
surfactant solution (Tween 60 and water) was heated to 75-80 ºC. The pre-heated surfactant 
solution was mixed with the heated mixture of lipids and Met to form a pre-emulsion using a 
hotplate magnetic stirrer. The mixture was sonicated for 2 minutes using a probe sonicator 
(Bandelin, 3100, Germany) and immediately immersed in an ice bath and stirred at 300 rpm after 
the sonication process finished. For more details on the composition refer to Table 1. 
 
2.3 Preparation of Met-SLN gel and conventional metformin gel 
To prepare the plain gel, carbopol (8%) was dispersed in water and kept overnight. Then the 
carbopol solution was neutralized by triethanolamine. To prepare met-SLN gel, 26 g of 
Metformin nanodispersion (equal  to 0.179% metformin) was mixed with 5 g plain gel under 
propeller homogenizer at 400 rpm. To prepare conventional metformin gel, metformin solution 
(equal to 0.179% metformin) was mixed with 5 g plain gel under propeller homogenizer at 400 
rpm. 
 
2.4 Physicochemical characterization  
The average particle size, polydispersity index (PDI)  and zeta potential of Met-SLN were 
determined by dynamic light scattering (DLS) method using a Zetasizer Nano ZS system 
(Malvern Instruments, Worcestershire, UK) at 25°C with an angle of 90° [6]. 
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2.5 Entrapment efficiency and Drug loading 
The Met-SLNs were subjected to centrifugation for 120 minutes at 27000 rpm (Sigma, Germany) 
to separate loaded Met from the dispersion. The supernatant was filtered using a syringe filter 
(pore size: 0.22 µm) and the amount of Met in the supernatant (free drug) was determined by 
HPLC Kneuer which was equipped with the Kneuer XDB-C18 column (5 µm, 4.6×250 mm). 
The mobile phase was a 60: 40 (v/v) phosphate buffer (1 mM) and Acetonitrile. The flow rate 
was 1ml/min and UV detection was carried out at 225 nm. The retention time of the drug was 4 
minutes. Drug entrapment efficiency (EE %) and drug loading were calculated by equations 1 
and 2 respectively:  
100% 


drug
drugdrug
initial
freeinitial
W
WW
EE          (Equation 1) 
 
    (Equation 2) 
Where Winitial drug is the amount of drug added in the formulation, Wfree drug is the amount of drug 
in supernatant and Wlipid is the amount of lipid [12]. 
 
2.6 Scanning Electron Microscopy (SEM):  
The SEM analysis was performed for morphological studies. The formulation coated with gold 
in nanostructure coating DSR1, and observed in HITACHI S-4160 SEM at an acceleration 
voltage of 20.0 kV and a magnification of 15000 X [13]. 
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2.7 Fourier Transforms Infrared (FT-IR) analysis  
For FT-IR studies, SLN were separated from SLN suspension by centrifugation using a 3-30ks 
sigma centrifuge. The separated SLNs was dried under reduced pressure using an alpha 1-2 ld 
plus freeze dryer (Marin Christ, Osterode, Germany). The dried SLNs, Met, Beeswax, 
cholesterol were used for FT-IR studies using a Perkin Elmer FT-IR spectrophotometer (Perkin 
FTIR-One, USA) from 400 to 4000 cm−1 to evaluate any alteration in the molecular levels. The 
sample was grounded with KBr and compressed into a suitable-size disk (13 mm) for 
measurement [6]. 
 
2.8 Differential Scanning Calorimetry (DSC) 
DSC measurements were performed on the bulk ingredients and Met-SLN powder using a Pyris 
6, PerkinElmer, USA). The samples (5 mg) of bulk lipid, drug and freeze-dried SLN 
formulations were weighed in aluminium pans and sealed. The sealed pans were kept under 
isothermal conditions at 20 ⁰ C for 30 minutes. After equilibration, DSC thermograms for the 
bulk samples and the Met-SLN powder were recorded from 20 ⁰ C to 250 ⁰ C at a heating rate of 
20 ⁰ C/min, under inert nitrogen gas atmosphere [6]. The DSC was calibrated using indium 
before testing the samples. 
 
2.9 Powder X-ray Diffractometer (PXRD) analysis 
The diffraction patterns were obtained using a D8 Advance X-ray diffractometer (Bruker-binary 
V2, Germany) (40 kV, 30 mA) to identify any changes in the crystal lattice of the materials after 
making SLNs. The crystalline characteristics of Met, beeswax, cholesterol and freeze-dried SLN 
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powder were analyzed by exposing them to Cu Kα radiation with a wavelength of 1.5406Å and 
scanned from 5.000º to 70.000º, 2Ɵ at a step size of 0.040º and step time of 1s  [6]. 
 
2.10 In vitro skin permeation study 
The study was compatible with the Ethical Guidelines for Investigations in Laboratory Animals 
and was approved by the Ethics Review Committee for Animal Experimentation of Mazandaran 
University of medical sciences. The abdominal skins of male Wistar rats (weighing 120-150 g) 
were anaesthetized (given 87 mg ketamine/kg of body weight and 13 mg xylazine/kg) and 
shaved using electric hand razors. After 48 h the rats were killed by chloroform inhalation and 
the abdominal skin was surgically removed. The skin was carefully cleaned from adhering 
subcutaneous fat and put in contact with a saline solution for 24 h before initiating the diffusion 
experiment. The skin was set in Franz cells (with a diffusional area of 3.8 cm2). The excised skin 
was placed between the cell halves and the dermis faced the receptor fluid. The receiver 
compartment was filled with deionised water. The diffusion cells were maintained at 32±0.5 ºC 
(using thermostatically controlled water which was circulated through a jacket surrounding the 
cell body throughout the experiments) and stirred at 150 rpm with magnetic stirring bars 
throughout the experiment. The receptor temperature is usually set to 32 degrees ºC to 
approximate normal skin conditions. 0.4 g (equal to 600 µg metformin) of Met-SLN gel (as a 
sample) and 0.4 g (equal to 600 µg metformin) of conventional metformin gel (as control) were 
spread out uniformly on the shaved dorsal surface in the donor compartment which was sealed 
from the atmosphere by gentle rubbing using a spatula. Samples were withdrawn from receiver 
medium at predetermined time intervals (4, 6, 8, 10 and 24 h) and an equivalent volume of fresh 
deionised water was added to the receiver phase. All samples were filtered by a syringe filter 
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(pore size: 0.22 µm) and analyzed by the HPLC method as described before (section 2.4). The 
skin was removed at the end of the permeation study and washed three times with deionised 
water and dried to calculate the amount of Met deposited within the skin. The removed skin was 
cut into small pieces using a pair of scissors and transferred to a tube and digested 24 h in water 
and then sonicated for 1 h with bath sonicator. The supernatant filtered through a filter paper and 
then filtered by a syringe filter (pore size: 0.22 µm) and quantified by HPLC for Met content [6]. 
 
2.11 Statistical analysis 
Results are shown as the mean ± standard deviation of at least three determinations (n = 3). The 
treated groups were compared to the control by analysis of variance (ANOVA) followed by the 
Tukey’s test. In the case of comparison of only two means, a t-test was performed. The statistical 
analysis was carried out using the SPSS 2021 software. A P-value < 0.05 was considered as 
significant. 
3. Results and discussion 
3.1 Nanoparticle characteristics (size, PDI, zeta potential and entrapment efficiency) 
analysis  
As the particle size of nanoparticles is an important characteristic of nanoparticles, therefore, a 
special attention was made on this factor. Table 1 shows the hydrodynamic diameter (intensity 
weighted mean diameter or the z-average diameter) of nanoparticles and the PDI reflects the 
quality of the dispersion (as an indication of the width of the particle size distribution) [14]. The 
PDI value usually ranges from 0 to 1 and the PDI values > 0.7 indicates a very broad distribution 
of particle sizes [15]. Table 1 shows that the size of nanoparticles and PDI value varied by the 
changes in the composition of surfactants. The use of binary mixtures of surfactants with low and 
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high HLB values generally ensures a better stability of emulsion droplets.  The surfactants with 
high and low HLB can be dispersed in the aqueous and the oily phase respectively leading to a 
more stability of the surfactant film at the interface [6]. Results showed that all formulations 
containing binary mixtures of surfactants have low particle size and Polydispersity index 
(compare F1 with F2-5 in Table 1 and Fig. 1). This clearly showed that the addition of co-
emulsifier (Span®60) reduced the particle size which could be an indication of a better stability 
of the dispersed product in the presence of the second emulsifier [14]. In other words, it was 
interesting to note that by adjusting the HLB value to 11.67 (near beeswax HLB) the particle size 
of SLNs significantly decreased from 790.733±117.75 nm to 203.8±15.356 nm (P<0.05) 
(compare F3 with F1in Table 1 and Fig. 1). The prepared SLNs dispersions by a binary mixture 
of surfactants had a PDI value ≤ 0.6 indicating an acceptable distribution of SLNs. Results 
showed that, although, the drug particles have positive charge, the zeta potential of the different 
formulations was negative and was in the range of -0.651 mV to -6.180 mV. It has been reported 
that the nonionic surfactants surprisingly exhibit a negative zeta potential around colloidal 
particles which could be due to the dipole nature of the ethoxy groups of nonionic surfactants 
[16]. The table also shows that by decreasing the ratio of Tween: Span from 1:0 to 1.11:1 the 
absolute zeta potential of SLNs increased from -0.651±0.315 mV (F1) to -6.18± 0.438 mV (F4) 
(P<0.05) and particles became more negatively charged. It seems that, the tendency of binary 
mixtures of Tween and Span increases compared to when single surfactant was used and binary 
surfactants can form more condensed barrier around colloidal particles and make particles more 
negatively charged as a result of more surfactants around nanoparticles (it was already discussed 
that nonionic surfactants produce negative charge around colloidal particles). But, this was not 
the case for formulation F5 where the amount of Tween becomes less than the amount of Span in 
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the formulation. This indicates that the ratio of Span to Tween has a significant effect on zeta 
potential and the highest zeta potential was obtained when the ratio of these two surfactants is 
close to each other. This is interesting results as the ratio of these two surfactants not only 
controls the zeta potential but also the size of nanoparticles (Table 1). Generally, smaller 
nanoparticles carries more surfactants around it and making nanoparticles more negatively 
changed. This was not the case when formulation F4 was compared to formulation F3 as apart 
from the size, it seems the amount of surfactants adsorbed by the nanoparticles can change the 
zeta potential.      
Somehow, the presence of high concentration of Span defects the film layer formed by Tween 
causing a reduction in the zeta potential (compare zeta potential of F4 and F5 in Table 1) as a 
result of less surfactants around nanoparticles. The electrophoretic mobility of the particles 
reduced by the surface coverage of SLNs and lowers the zeta potential [14]. As the critical 
micelle concentration of Tween 60 is relatively low (about 0.022 mM), therefore, the 
concentration of Tween 60 monomers in the dispersion medium should be low [17]. This fact 
indicates that adsorption of surfactant monomers onto the hydrophobic surfaces of the lipids is 
more likely to happen rather than forming micelles. At the interface between two immiscible 
liquids such as oil and water, surfactants will orientate themselves with their hydrophilic group 
in the water and their hydrophobic group in the oil [14]. Also, a further reduction in the ratio of 
Tween:Span to 0.583:1 in F5 caused a reduction in the zeta potential of SLNs from -6.18± 0.438 
mV to -3.596±0.255 mV.  The surface of particles perfectly is covered by nonionic surfactants 
and use of the high concentration of second surfactant (in this case Span) probably can break 
fully the coverage ability of the first surfactant [14]. Based on the effect of the ratio of binary 
surfactants, it can be concluded that the use of the second surfactant probably at  high 
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concentration can break the surfactant film around the particles and reduces the zeta potential. In 
the current study, the zeta potential value was not considered a primary parameter in the 
selection of the optimal formulation. SLNs perfectly covered by nonionic surfactants like Tween 
and Span 60 tend to remain stable because of greater steric stabilization despite having a lower 
zeta potential and less electrostatic stabilization [14]. Results of the EE% measurements showed 
that the EE% of the different formulations were in the range 45.986±9.209% to 28.503±5.610%. 
The loading quantity could be affected by the drug solubility and miscibility in the lipid matrix, 
and the lipid phase polymorphic state. To decrease the degree of lipid phase crystallinity and to 
increase loading capacity, cholesterol was added to the lipid phase [18].  Metformin has a high 
tendency to escape from lipid matrix due to its high solubility in water [19]. As particle size 
decreases the specific surface area increases and thus drug loading decreases. Ebrahimi et al. 
showed that the loading values increased as the particle sizes increased [20]. The reverse 
relationship between particle size and loading parameters (loading efficiency and entrapment 
efficiency) has been shown in previous studies. The higher surface area increases the mobility 
and tendency of the drug to escape from the matrix. As in smaller particles, the total particle 
surface is larger and drug repulsion is higher, therefore, this resulted in lower EE% [20]. The 
highest EE% belonged to formulations with highest HLB value= 14.9 with larger particle size. 
Xu et al prepared SLNs containing Met for cellular and mitochondrial uptake. The mean particle 
size, zeta potential, entrapment efficiency, and loading efficiency of Met-SLNs were 102.3±4.16 
nm, –21.25±4.89 mv, and 26.25±2.59% respectively [12]. In another study, Ngwuluka et al 
prepared Met-loaded solid lipid nanoparticles (SLN) for Colon Cancer by double emulsification-
solvent evaporation employing cold homogenization. The particle size,  zeta potential and 
percentage drug entrapment for their optimized SLN were 195.01±6.03 nm, −17.08±0.95 mV 
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and 29.30±2.29% respectively [21]. In another study, Sharma et al prepared Met-loaded solid 
lipid nanoparticles for transdermal delivery by solvent diffusion technique. The particle size, zeta 
potential and percentage drug entrapment for their optimized SLN were 242±5, +27 mV and 
94.62±0.02 % respectively [22]. The advantage of the current method used to prepare Met-SLN 
over other published method is that no organic solvent was used, and the nanoparticles were 
incorporated into the gel base which could be a finished product. In addition, none of the above 
studies investigated the effect of Span:Tween ratio which is needed to optimize Met-SLN to have 
a better performance. The optimized Met-SLNs (F3) prepared by ultra-sonication method had the 
particle size of 203.8±15.356 nm, PDI of 5.083±0.0085, the zeta potential of -3.7.4±5.4.0 mV 
and the percentage drug entrapment of 32.92±1%. It was interesting to note that the 
concentration of metformin used in the current study was 7.5 times higher than the concentration 
of the drug used in another study [9] and the loading of drug in the current study was over 2 
times higher than Met-SLN reported by Ngwuluka et al [18]. Gandomi et al loaded 
Ciprofloxacin HCl, a water-soluble drug, by a microemulsion technique in SLNs. Comparing 
their results with the current study showed that the type of drug can change the EE and DL 
values. For example, they produced a lower mean particle size for SLNs (95 ± 3 nm) and lower 
their zeta potential (-1.9 mv) compared to the current study [9]. Shah et al loaded ciprofloxacin 
HCl in SLNs and they showed that changing the amount of lipid, stirring speed and stirring time 
could remarkably modify the entrapment efficiencies and particle size of the prepared SLNs. The 
particle size of an SLN was in the range of 159 nm to 246 nm and The highest entrapment 
efficacy (EE) was reported to be 39.5% [10]. In another study, Kazemi et al loaded gentamicin 
sulfate, a water-soluble antibiotic, by an ultrasonication/high speed homogenization technique on 
SLNs and they showed that the average particle size of gentamicin-loaded SLNs was 282.3 nm 
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and its zeta potential was +8.16 mV with drug-loading efficiency of 40%. Although, all the drugs 
used in the mentioned studies were water-soluble, but the solubility of isoniazid was extremely 
higher than the drugs used in other studies. The water solubility of isoniazid, ciprofloxacin HCl 
and gentamicin at 25°C is 125, 35 and 50.0 mg/mL respectively but metformin HCl with a 
solubility of 1060 mg/mL at 25°C was much higher compared to the other hydrophilic drugs 
used. 
 
3.2 SEM analysis 
Particle size and morphology of nanoparticles were also studied by scanning electron microscopy 
(SEM) (HITACHI S-4160). The image obtained for F3 by SEM (Fig.2) showed the typical 
morphological aspects of nanoparticles. The SEM image showed that the particles were 
segregated, uniform in size and spherical in shape.  
 
3.3 FT-IR  
Figure 3 demonstrates the infrared spectra of Met, cholesterol, beeswax and Met-SLN 
(formulation 3). The diagnostics peaks of Met were found in the FT-IR spectra of Met-SLN 
formulation. Cyanides group’s peaks of Met were still recognizable, which could be an 
indication of a good entrapment of Met in a lipid matrix. On the basis of FT-IR results shown, 
the results proved that there is no chemical interaction between the drug and its excipients as 
main diagnostic peaks for the drug are apparent in Figure 3. The results of FT-IR spectra of pure 
Met, cholesterol and beeswax are summarized as follows: 
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Met: 4470 cm-1 (first N-H, stretching), 4293 cm-1 (second N-H, stretching), 3174 cm-1 (C-H, 
stretching), 1623 cm-1 (C=N, stretching), 1446 cm-1 (C-H, bending), 1059 cm-1 (C-N, 
stretching).Cholesterol: 3400 cm-1 (OH, stretching), 3035cm-1 (cyclic C-H, stretching), 3000-
2850cm-1 (methyl C-H, stretching), 1445 cm-1 (C=C, stretching), 1220 cm-1(C-O stretching). 
Beeswax: 3000 cm-1 (OH, stretching), 2950-2850cm-1 (C-H, stretching), 1737cm-1 (C=O, 
stretching), 1470-1376 cm-1 (C-H, bending), 745 cm-1(long chain hydrocarbon and steric group, 
Vibration). 
 
3.4 Differential Scanning Calorimetry (DSC) 
The thermal behavior of metformin, beeswax, cholesterol and Met-SLN powder (F3) were 
investigated by DSC and their DSC thermograms are shown in Figure 4. Met and cholesterol 
thermograms showed a single sharp endothermic peak at about 235 ºC and 150 ºC respectively 
corresponding to their melting points, an indication of highly crystalline nature for these two 
materials. Beeswax showed an endothermic peak around 40-66 ºC corresponding to its melting 
point. The DSC thermograms of investigated SLN formulation only contained the endothermic 
peak around beeswax melting point, but the endothermic peak of drug disappeared (Fig.4) which 
suggests that the metformin in SLN is in an amorphous state or is molecularly dispersed within 
the SLN. 
 
3.5 Powder X-ray Diffractometer (PXRD) analysis 
Figure 5 illustrates the X-ray diffraction (PXRD) pattern of Met, cholesterol, beeswax and Met-
SLN (F3). The PXRD of Met revealed the distinct peaks at 2θ: 12.92◦, 12.596◦, 17.463◦, 
22.662◦, 23.119◦, 24.373◦, 25.254◦, 26.282◦, 27.058◦, 29.272◦, 31.189◦, 32.57◦, 34.22◦, 37.024◦, 
37.52◦, 39.2◦, 40.6◦, 42◦, 44.58◦, 46◦, 47.3◦, 48.7◦, 49.63◦ [23]. The cholesterol showed the peaks 
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at 2θ: 5.272◦, 10.604◦, 12.83◦, 15.501◦, 16.972◦, 17.393◦, 18.154◦, 23.565◦, 26.244◦, 37.151◦, 
42.404◦. These sharps peaks for both of Met and cholesterol confirmed the highly crystalline 
nature of them. The beeswax showed the peaks at 2θ: 8.698◦, 19.553◦, 21.656◦, 24.025◦, 30.12◦, 
36.252◦, 40.45◦, 47.33◦, 55.13◦ indicating the crystalline nature of the beeswax. The PXRD 
pattern of Met-SLN showed the peaks at 2θ: 21.384◦, 23.717◦, 40.23◦, 42.97◦ and 48.34◦. As 
observed in Fig.5, lipid peaks did not shift but had a reduced intensity as compared to free lipid. 
This may be attributed to the incorporation of cholesterol and Met between the parts of the 
beeswax leading to a change in the crystallinity of the lipid. The results showed a good 
entrapment of Met in beeswax without any interaction which are aligned with FT-IR and DSC 
analysis. 
 
3.6 In vitro percutaneous absorption study 
To assess the performance of both Met-SLN nanogel and compare it with the performance of the 
standard Met gel (just containing 0.15% Met in carbopol gel) in vitro percutaneous absorption 
was performed. In this test, the ability of Met-SLN to penetrate different layers of skin and its 
skin permeation were considered and the results are shown in Figures 6 and 7. Nanogel showed 
an increased penetration into and through the skin layers. This indicates that the novel Met-SLN 
gel formulation can have a better local effect compared to Met gel. Results suggest that the more 
anti-ageing effect could be expected for drug-loaded SLNs gel compared to plain drug gel. 
Madan et al also showed that skin deposition of the mometasone from gels containing SLN was 
2.67 times more than marketed cream and 20 times more than plain drug loaded gel [24].  
Bhalekar et al also showed that the miconazole nitrate -SLN gel could signiﬁcantly increase the 
accumulative uptake of miconazole nitrate in the skin over the marketed gel and showed a 
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signiﬁcantly enhanced skin targeting effect [25]. Sharma et al also showed that the high 
cumulative amount of Met is permeated from Met SLN transdermal patches [22]. The results 
obtained from in vitro percutaneous absorption in the present study indicated that lipid 
nanoparticles gel are promising in local delivery for Met and other hydrophilic drugs and 
stimulating new and deeper investigations in the field. 
 
4. Conclusion 
The present study suggests that solid lipid nanoparticles are suitable carriers for skin delivery of 
Met and other hydrophilic drugs. This carrier can increase the dermal delivery of metformin with 
a higher concentration into deeper layers of the skin. In order to achieve more stable 
nanoparticles and localize the delivery of metformin, the solid lipid nanoparticle formulations 
need optimization and the research showed that Span: Tween ratio was a critical parameter to 
optimize metformin nanogel formulation to achieve a good delivery to the skin. 
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Table 1. Component and physicochemical properties of investigated Met- SLN (% w/w). The data are the mean and standard deviation 
of three determinations (n = 3). Metformin: Met; PDI: polydispersity index; zeta potential; EE: entrapment efficiency.  
HLB 
EE 
(%) 
Zeta potential ( 
mV) 
PDI 
 
Size 
(nm) 
Water 
(%) 
Tween 
60 
(%) 
Span 
60 
(%) 
Beeswax 
(%) 
Cholesterol 
(%) 
Met 
(%) 
Formulation 
03.1 45.98±9.20 -5.600±5.40 0±0 790±117 89.60 6.81 0 3.22 0.179 0.179 F1 
04..1 28.50±5.61 -..00±5.04 5.030±0.01 258±6 89.60 5.73 1.07 3.22 0.179 0.179 F2 
00.67 32.92±1.75 -3.7.4±5.4. 5.083±0.00 203±15 89.60 4.65 2.15 3.22 0.179 0.179 F3 
05.56 37.32±0.93 -6.01±5.33 5.010±0.01 263±8 89.60 3.58 3.22 3.22 0.179 0.179 F4 
1.30 29.38±3.55 -4.016±5..6 5.047±0.00 389±50 89.60 2.50 4.30 3.22 0.179 0.179 F5 
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Figure 1.  Particle size, polydispersity index, zeta potential and entrapment efficiency for various 
formulations (error bars are standard deviation, ANOVA test followed by Tukey’s test was 
carried out between the formulations. The difference was significant p < 0.05; n = 3). 
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Figure 2. SEM micrographs of Met-solid lipid nanoparticles (Met-SLN3). 
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Figure 3. FT-IR spectra of Met, beeswax, cholesterol and Met-SLNAC
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Figure 4. DSC traces of Met, beeswax, cholesterol and Met-SLN 
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Figure 5. XRD of Met, beeswax, cholesterol and Met-SLN 
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Figure 6. Amount of Met penetrating to the skin layers (Dermal delivery) (error bars are standard 
deviation, sample represents Met-SLN and standard formulation is the Met solution gel 
containing the same concentration of Met; t-test was carried out between the sample and 
standard. The difference was significant p < 0.05; n = 3).  
 
  
Figure 7. Cumulative amount of Met permeated across rat skin (data is mean and standard 
deviation of three determinations, n = 3; ANOVA test followed by Tukey’s test showed that the 
effect of time and formulation on Met permeation was significant p < 0.05). Sample represents 
Met-SLN gel and standard is Met solution gel containing the same concentration of Met. 
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